In this week's C&EN (by Rick Mullin):
Bachem inks peptide supply pact
Bachem has signed an agreement to supply large volumes of peptides to an undisclosed customer. Manufacturing will primarily take place at the company’s large-scale production facility currently under construction in Bubendorf, Switzerland. The Swiss firm says the order commits it to supplying a volume of peptides valued at over $530 million between 2027 and 2031. The facility at Budendorf, scheduled to open in 2024, will nearly double its manufacturing capacity for peptides and oligonucleotides.
Bold prediction: I'm curious to see if this will increase over the next 1-3 years. I have a real feeling about this...
What is the nature of the "feeling" you have about the increase in capacity? That the Swiss are correct in their bet that they will be successful? Just curious.
ReplyDelete